WO2004066954A3 - A therapeutic composition for the treatment of hiv-1 and hiv-2 - Google Patents

A therapeutic composition for the treatment of hiv-1 and hiv-2 Download PDF

Info

Publication number
WO2004066954A3
WO2004066954A3 PCT/US2004/002536 US2004002536W WO2004066954A3 WO 2004066954 A3 WO2004066954 A3 WO 2004066954A3 US 2004002536 W US2004002536 W US 2004002536W WO 2004066954 A3 WO2004066954 A3 WO 2004066954A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
treatment
therapeutic composition
aids
stages
Prior art date
Application number
PCT/US2004/002536
Other languages
French (fr)
Other versions
WO2004066954A2 (en
Inventor
Jelen Boguslaw
Original Assignee
Jelen Boguslaw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/353,483 external-priority patent/US20030203045A1/en
Application filed by Jelen Boguslaw filed Critical Jelen Boguslaw
Priority to CA002514252A priority Critical patent/CA2514252A1/en
Priority to AU2004206996A priority patent/AU2004206996A1/en
Priority to JP2006503151A priority patent/JP2006516633A/en
Priority to EP04706521A priority patent/EP1589961A4/en
Publication of WO2004066954A2 publication Critical patent/WO2004066954A2/en
Publication of WO2004066954A3 publication Critical patent/WO2004066954A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A pharmaceutical mixture and a method of its production of a therapeutic composition for blocking the HIV-1 and HIV-2 virus replication in the CD4+ cells of the human immune system in all stages of that viral infection, and in AIDS for the treatment of HIV in a patient in need of such treatment.
PCT/US2004/002536 2003-01-29 2004-01-29 A therapeutic composition for the treatment of hiv-1 and hiv-2 WO2004066954A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002514252A CA2514252A1 (en) 2003-01-29 2004-01-29 A therapeutic composition for the treatment of hiv-1 and hiv-2
AU2004206996A AU2004206996A1 (en) 2003-01-29 2004-01-29 A therapeutic composition for the treatment of HIV-1 and HIV-2
JP2006503151A JP2006516633A (en) 2003-01-29 2004-01-29 Therapeutic compositions for treating HIV-1 and HIV-2
EP04706521A EP1589961A4 (en) 2003-01-29 2004-01-29 A therapeutic composition for the treatment of hiv-1 and hiv-2

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/353,483 US20030203045A1 (en) 2002-04-30 2003-01-29 Therapeutic composition for the treatment of HIV-1 and HIV-2
US10/353,483 2003-01-29

Publications (2)

Publication Number Publication Date
WO2004066954A2 WO2004066954A2 (en) 2004-08-12
WO2004066954A3 true WO2004066954A3 (en) 2005-03-17

Family

ID=32823743

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/002536 WO2004066954A2 (en) 2003-01-29 2004-01-29 A therapeutic composition for the treatment of hiv-1 and hiv-2

Country Status (9)

Country Link
EP (1) EP1589961A4 (en)
JP (1) JP2006516633A (en)
KR (1) KR20050094461A (en)
CN (1) CN1747726A (en)
AU (1) AU2004206996A1 (en)
CA (1) CA2514252A1 (en)
RU (1) RU2005123957A (en)
WO (1) WO2004066954A2 (en)
ZA (1) ZA200505977B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101810625B (en) * 2010-04-09 2012-05-23 上海新康制药厂 Application of taraxasterol

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970212A (en) * 1982-05-18 1990-11-13 Nowicky Wassili Method of treating human illnesses which compromise the ability to mount an effective immunological response
CA1337047C (en) * 1988-08-18 1995-09-19 Peter Dodd Cooper Gamma inulin compositions
US5053419A (en) * 1989-03-31 1991-10-01 The Children's Medical Center Corporation Treatment of AIDS dementia, myelopathy and blindness
US5977073A (en) * 1991-06-06 1999-11-02 Life Sciences' Technologies, Inc. Nutrient composition for treatment of immune disorders
RU2107502C1 (en) * 1997-03-27 1998-03-27 Открытое акционерное общество "Ветеринарные препараты" Iodine monochloride, veterinary preparation possessing wide range of action
WO2001000194A2 (en) * 1999-06-29 2001-01-04 Jacobs Robert H A method for optimizing immune activity in the treatment of auto-immune diseases and chronic immune conditions
RU2195277C2 (en) * 2001-02-09 2002-12-27 Третьяков Василий Васильевич Method of treatment of hiv-infection
GB2374008B (en) * 2001-04-04 2005-03-16 John Carter Pharmaceutical compositions comprising copper and zinc
PL353693A1 (en) * 2002-04-30 2003-11-03 Bogusław Jeleń Compound pharmaceutical for inhibiting replication of hiv-1 and hiv-2 viruses in the cd4+ cells of human immunological system at all stages of infection and in the aids syndrome as well as method of manufacture of compound pharmaceutical for inhibiting replication of hiv-1 and hiv-2 viruses in the cd+ cells of human immunological system at all stages of infection and in the aids syndrome

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] GEORGIOU N.A. ET AL.: "HUman immunodeficiency of virus type I replication inhibition by the bidentate iron chelators CP502 and CP511 is caused by proliferation inhibition and onset of apoptosis", XP002983825, accession no. STN Database accession no. 2002:312731 *
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, vol. 32, no. SUPPL 1, 26 April 2002 (2002-04-26), pages 91 - 96 *

Also Published As

Publication number Publication date
RU2005123957A (en) 2006-01-27
JP2006516633A (en) 2006-07-06
AU2004206996A1 (en) 2004-08-12
KR20050094461A (en) 2005-09-27
CA2514252A1 (en) 2004-08-12
CN1747726A (en) 2006-03-15
WO2004066954A2 (en) 2004-08-12
EP1589961A4 (en) 2006-02-15
EP1589961A2 (en) 2005-11-02
ZA200505977B (en) 2006-05-31

Similar Documents

Publication Publication Date Title
SG170825A1 (en) Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
HUP0203437A2 (en) Use of resorcinol derivatives for producing pharmaceutical compositions for treatment of immune diseases
CA2321523A1 (en) Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
WO2004096818A3 (en) Method and compositions for identifying anti-hiv therapeutic compounds
WO2008118849A3 (en) Hiv-1 protease inhibitors
YU27203A (en) Pyrazole derivatives for the treatment of viral diseases
WO2006044968A3 (en) Combination therapy for treating viral infections
HUP0202502A2 (en) Peptides that block viral infectivity and methods of use thereof
WO2002034284A3 (en) Methods of therapy for hiv infection
WO2005111079A3 (en) Hiv vaccine immunogens and immunization strategies to elicit broadly-neutralizing anti-hiv-1 antibodies against the membrane proximal domain of hiv gp41
MX2021010972A (en) Pharmaceutical dosage form for application to mucous membranes and methods for producing same.
WO2005089231A3 (en) Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide
DE60239682D1 (en) VACCINE, WHICH GP120 INCLUDES WITH NEF AND / OR ACT, TO IMMUNIZE AGAINST HIV
WO2003061602A3 (en) Combination therapy for treatment of hiv infection
WO2006045616A3 (en) β-L-N4-HYDROXYCYTOSINE DEOXYNUCLEOSIDES AND THEIR USE AS PHARMACEUTICAL AGENTS IN THE PROPHYLAXIS OR THERAPY OF VIRAL DISEASES
WO2002078631A3 (en) Improved conditionally replicating vectors for inhibiting viral infections
WO2004066954A3 (en) A therapeutic composition for the treatment of hiv-1 and hiv-2
ZA202306360B (en) Substituted pyridotriazine compounds and uses thereof
WO2004029201A3 (en) Peptide derivative fusion inhibitors of hiv infection
WO2007137591A8 (en) Hiv vaccine
AU2003217604A1 (en) Method of treating hiv infection by preventing interaction of cd4 and gp120
WO2005058237A3 (en) Treatment of aids
MX2022015438A (en) Dispersible tablet formulations comprising dolutegravir.
WO2004039945A3 (en) Preventive and therapeutic aids vaccines
WO2003072750A3 (en) Expression of hiv-related proteins in plants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1237/KOLNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006503151

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2514252

Country of ref document: CA

Ref document number: 1020057013692

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200505977

Country of ref document: ZA

Ref document number: 1442/KOLNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 541545

Country of ref document: NZ

Ref document number: 2004206996

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004706521

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20048039434

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2004206996

Country of ref document: AU

Date of ref document: 20040129

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004206996

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2005123957

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020057013692

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004706521

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004706521

Country of ref document: EP